The mountain cedar pollen tsunami hits south-central Texas annually with a ferocity and dependability that have made the season a mainstay in allergy research.
San Antonio, TX (PRWEB) July 25, 2013
In the July 2013 issue of the Annals of Allergy, Asthma and Immunology, investigators in San Antonio, Texas describe the use of the mountain cedar season as a valuable tool for the assessment of new allergy medications and vaccines. The article, entitled "The mountain cedar model in clinical trials of seasonal allergic rhinoconjunctivitis," discusses the immune features of the pollen, reviews published studies and presents the daily pollen grain counts recorded over 18 years.
Dr. Charles Andrews, a Principal Investigator of the Biogenics Research Chamber and the lead author of the article notes that, “the mountain cedar pollen tsunami hits south-central Texas annually with a ferocity and dependability that have made the season a mainstay in allergy research.”
Thirty-eight studies from the scientific literature are presented, recognizing that many other studies, particularly generic drug trials, are unpublished. Analysis of the pollen counts provided by Dr. Paul Ratner reveals uniformity over many years that allows advance planning for successful natural season trials. Mountain cedar pollen has also been found to elicit major nasal and eye symptoms in multiple studies in the Biogenics Research Chamber. Utilizing mountain cedar pollen in the chamber model provides controlled trials for the evaluation of medications and vaccines, as well as allowing study of the basic inflammatory mechanisms of acute allergic reactions.
About the Company:
Biogenics Research Chamber located in San Antonio, Texas is the only large permanent pollen exposure testing facility in the United States. Dr. Robert Jacobs, Dr. Daniel Ramirez and Dr. Charles Andrews are the owners and Principal Investigators. The facility has a large chamber capable of testing up to 60 allergic participants at a time and a moderate sized chamber for testing up to 32 subjects. Both chambers utilize unique engineering and pollen delivery systems. Two additional chambers are being constructed. Compared to natural season allergy studies, the chambers offer controlled conditions without pollen concentration variation and weather interruptions. Proof of concept, dose-ranging, and onset of action studies are performed for pharmaceutical and vaccine trials. In addition to commercial studies, the Biogenics Research Chamber has performed multiple academic trials examining the basic mechanisms of allergy.